3 results
Approved WMOPending
Primary objective:• Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with pembrolizumab in subjects with relapsed/refractory metastatic NSCLCSecondary objectives:• Evaluate time to onset and durability of the anti tumor…
Approved WMORecruiting
We hypothesize that Kenalog-40, Kenalog-10 and Depo-Medrol 40 mg/ml have a different effectiveness in treating trigger fingers in both primary as secondary outcomes.
Approved WMOPending
To find a suitable treatment option for the 25% of HS patients who are therapy-resistant. Additionally, we expect a faster healing time of the wounds, meaning that even if patients respond to current treatment, HBOT may improve their quality of life…